Search for drugs:
Typing the drug name to query
ALEMTUZUMAB
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- The effect of multiple doses of alemtuzumab (12 mg/day for 5 days) on the QTc interval was evaluated in a single-arm study in 53 patients without malignancy. No large changes in the mean QTc interval (i.e., >20 ms) were detected in the study. A mean increase in heart rate of 22 to 26 beats/min was observed for at least 2 hours following the initial infusion of alemtuzumab. This increase in heart rate was not observed with subsequent doses.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
11
24081
Other ADRs
61431
38320156
Odds Ratio = 0.285
Drug Property Information
ATC Code(s):
- L04AA34 - alemtuzumab
- L04AA - Selective immunosuppressants
- L04A - IMMUNOSUPPRESSANTS
- L04 - IMMUNOSUPPRESSANTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:ALEMTUZUMAB
Active Ingredient UNII:3A189DH42V
Drugbank ID:DB00087
PubChem Compound:N/ADIR Classification
CAS Number:
Dosage Form(s):injection
Route(s) Of Administrator:intravenous
Daily Dose:
- 0.13 mg/day L04AA34
Chemical Structure: 
SMILE Code:
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.